A panel of HTS assays was developed using the Transcreener platform to accelerate the development of selective helicase inhibitors.
To accelerate the development of selective helicase inhibitors while avoiding off-target effects, especially with helicases that promote tumor immunity, a panel of HTS assays was assembled using the Transcreener ADP assay for homogenous detection of RNA-dependent ATPase activity. These assays will enable screening and hit-to-lead/SAR for DDX helicases that drive tumorigenesis and selectivity profiling to avoid off-target effects with RLR helicases that promote tumor immunity.
Download Now
Asset 5: Poster: Assays for DDX3, DDX5, DDX17, RIG-I, and MDA5
PDF, Size 0 kb
